Key players in Chiles GLP-1 segment: Novo Nordisk Market leader with Ozempic, Victoza, and Wegovy Eli Lilly Bringing innovation with Mounjaro (Tirzepatide) Sanofi Providing Soliqua, a GLP-1 + insulin combo CFR Pharmaceuticals (Abbott) Local affiliate with strong market access Biocon Expanding biosimilar reach in Latam AstraZeneca Strategic focus on metabolic & cardiovascular synergy With increasing physician adoption and patient demand, Chile is evolving into a high-opportunity market for obesity and type 2 diabetes therapies
What if I regain weight after stopping
Effectiveness Clinical trials have demonstrated significant weight loss results with Saxenda
Is topical "weaker" than injectable
Compounded semaglutide and tirzepatide are not FDA-approved, and are used off-label when clinically appropriate
Through diligent research, vigilant clinical practice, and empowered patient participation, the medical community can navigate these challenges, optimizing treatment outcomes while safeguarding patient health